Recombinant human interferon alpha 2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitro

Transcript

1 Acta Pharmaceutica Sinica 2014, 49 (11): α2b 1, 1, 1, 2, 2, 1* (1., ; 2., ) : α2b RT-PCR α2b A (CPE) α2b B (HPIV) (RSV), 3, α2b , (RBV) α2b A RNA, α2b B 2.74,, α2b,,,, : α2b; ; ; MTT ; RT-PCR : R965 : A : (2014) Recombinant human interferon alpha 2b broad-spectrum anti-respiratory viruses pharmacodynamics study in vitro WANG Hui-qiang 1, MA Lin-lin 1, JIANG Jian-dong 1, PANG Rui 2, CHEN Yu-jun 2, LI Yu-huan 1* (1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing , China; 2. Harbin Pharmaceutical Group Bio-Engineering Co., Ltd., Harbin , China) Abstract: This study is to investigate the effect of recombinant human interferon alpha 2b against broad-spectrum respiratory viruses in vitro. At the cellular level, the effect of the recombinant human interferon alpha 2b on influenza A virus was detected using real-time fluorescence quantitative RT-PCR. The effects of the recombinant human interferon alpha 2b on influenza B virus, parainfluenza virus, respiratory syncytial virus (RSV) and coronavirus were detected using cytopathic effect (CPE) method. In this study, the therapeutic index of recombinant human interferon alpha 2b anti-hpiv was , the therapeutic index of recombinant human interferon alpha 2b anti-rsv was , the therapeutic index of recombinant human interferon alpha 2b anti-coronavirus was more than , and the antiviral effect of recombinant human interferon alpha 2b was better than ribavirin (RBV). Recombinant human interferon alpha 2b has a stronger inhibitory effect on different influenza A virus RNA than drug control. The therapeutic index of recombinant human interferon alpha 2b anti-influenza B virus was 2.74, with modest effect. Recombinant human interferon alpha 2b in vitro has broad spectrum antiviral activities, low toxicity and high therapeutic index. Recombinant human interferon alpha 2b is expected to become the efficient medicine in clinical against respiratory viruses, as well as provide : ; : : (2012ZX ); (2012ZX ). * Tel: , Fax: , yuhuanlibj@126.com

2 1548 Acta Pharmaceutica Sinica 2014, 49 (11): better services for prevention and treatment of respiratory viruses infections. Key words: recombinant human interferon alpha 2b; respiratory virus; cytopathic effect; MTT; qrt-pcr,,,,,, 90%, [1], [2],, H5N H1N H7N9 [3, 4],,,,,,, 60% 80%, [5],,,, [6] (IFN), 3 : I (IFN-α IFN-β IFN-ω), II (IFN-γ) III (IFN-λ1 IFN-λ2 IFN-λ3) IFN,,,,, RNA DNA IFN ; RNA, RNA IFN RNA, DNA RNA, IFN [7],, ; (NK ) T, [8],,,,, α1, α2, α1 α2,,, [9], [1, 7], CPE MTT qrt-pcr α2b, (Hep2) (HEL) (A549) (MDCK) (coronavirus) (HPIV-3) (RSV) A/FM/1/47 (H1N1) (ATCC),, 80 : A/ /1109/2010 (H1N1) (LNZX) A/ /196/2009 (H3N2) (FJTA) A/ /312/2006 (H3N2) (JXDH) B/ /13/97,, 80 F-12K Nutrient Mixture (1X) Non-Essential Amino Acids (NEAA) (100X) (GIBCO ), Minimum Essential Medium (MEM) ph (PBS) ( ) α2b, U/, : ( ); (oseltamivir phosphate, ); (ribavirin, RBV),

3 : α2b ( ); (amantadine, ) (MTT) (BSA) (TPCK) (Sigma ); (DMSO, ) 96 ( Corning ); (Model 3111) ( Thermo ); (ELX808, BioTeK ); 7500-fast real time PCR system (Applied Biosystems ); ( NUAIRE ); ( ) : 40 ml 1% BSA, 5 ml (100X), 5 ml NEAA 1 mg TPCK 500 ml MEM F-12K Nutrient Mixture (1X) 0.08% BSA 2 μg ml 1 TPCK, 4, 37 : 10 ml, 5 ml (100X) 500 ml F-12K Nutrient Mixture (1X) 2%, 4, 37 CPE, ( ), 4+ ( 75% 100%) 3+ ( 50% 75%) 2+ ( 25% 50%) 1+ ( 0 25%) 0+ ( ), 0+ qrt-pcr 3- (glyceraldehyde phosphate dehydrogenase, GAPDH) : 5'-CTCTGGAAAGCTGTGGCGTGA TG-3' 5'-ATGCCAGTGAGCTTCCCGTTCAG-3'; M2 : 5'-GACCRA TCCTGTCACCTCTGAC-3' 5'-GGGCATTYTGGAC AAAKCGTCTACG-3' Invitrogen RNA (RNeasy Mini kit) QIAGEN, qrt-pcr (TransScript TM Green One-Step qrt-pcr SuperMix) TransGen Biotech (MTT ) Hep2 : / h, 2% FBS F-12K Nutrient Mixture (1X) 3, ( ), 72 h ( / ) 96 h ( / ), MTT, 5 mg ml 1 MTT 10 μl 37 4 h, DMSO 150 μl, 490 nm (OD) HEL : / h, 2% FBS F-12K Nutrient Mixture (1X) 3, ( ), 72 h, MTT ( ) A549 : / h, 1% NEAA 0.08% BSA F-12K Nutrient Mixture (1X) 3, ( ), 72 h, MTT ( ) MDCK : / h, 1% NEAA 0.08% BSA MEM 3, ( ), 72 h, MTT ( ), Reed-Muench TC 50, : 50 B TC50 Antilog( A D) C B A: log<50% B: 50% C: 50%, D: log (CPE ) Hep / 96, 16 h,, 100 μl 100TCID μl, 4+, Reed-Muench IC 50 ( TC 50 ) (SI = IC 50 / TC 50 ) (CPE ) Hep / 96, 16 h,, 100 μl 100TCID μl, 4+, Reed-Muench IC 50 ( TC 50 ) (SI = IC 50 / TC 50 ) (CPE ) HEL / h, 100 μl 100TCID 50 2 h, 2 h

4 1550 Acta Pharmaceutica Sinica 2014, 49 (11): , 4+, Reed-Muench IC 50 ( TC 50 ) (SI = IC 50 / TC 50 ) B (CPE ) MDCK / h, PBS 1 ( ), 100 μl 100TCID 50, 2 h,,, 2, 4+, Reed-Muench IC 50 ( TC 50 ) (SI = IC 50 / TC 50 ) A (qrt-pcr ) A / 6, 16 h, PBS 1 ( ), 600 μl 100TCID 50, 2 h 48 h,, RNeasy Mini Kit RNA, RNA TransScript TM Green One-Step Qrt-PCR SuperMix 7500-fast real time PCR system (Applied Biosystems), 20 μl 50 5 min, s, 40 (94 5 s, s, s) (%) ( ), Reed-Muench IC 50 ( TC 50 ) (SI = IC 50 / TC 50 ) Flu-A Ct Flu-A Ct % 1/ 2 ( ) 100% GAPDH Ct GAPDH Ct SPSS13.0 t RNA 1 MTT α2b, MTT 1 : Hep /, α2b TC U ml 1 ; /, α2b TC U ml 1 ; HEL /, α2b TC 50 > U ml 1 ; A /, α2b TC 50 > U ml 1 ; MDCK /, α2b TC U ml 1 α2b, 2 CPE, CPE α2b 3 2, α2b (IC 50 ) U ml 1, SI ; IC U ml 1, SI ; IC U ml 1, SI > α2b 3,, B M2, M2 qrt-pcr, CPE, MDCK Table 1 TC 50 of drugs on cells (MTT). : Not tested TC 50 (U ml 1 or μg ml 1 ) Cell Interferon alpha 2b Ribavirin Oseltamivir phosphate Amantadine Hep2 ( ) ± ± 1.73 Hep2 ( ) ± ± HEL ( ) > ± 0.00 >1 000 ± 0.00 A549 ( ) > ± ± ± ± MDCK ( ) ± ± ± ± Table 2 IC 50 of drugs on virus (CPE) Virus Interferon alpha 2b Ribavirin IC 50 /U ml 1 SI IC 50 /μg ml 1 SI HPIV ± ± ± ± 7.95 RSV ± ± ± ± 7.26 Coronavirus ± > ± ± 1.30 >93.98 ± 12.24

5 : α2b 1551 B 3 MDCK, α2b B/ /13/97 IC U ml 1, SI 2.74; 10 μg ml 1 B/ /13/97 IC μg ml 1, SI ; 40 μg ml 1, 10 μg ml 1 B/ /13/ 97 α2b B, Table 3 IC 50 of drugs on influenza virus B (CPE) MDCK ( ) Compound IC 50 /U ml 1 or μg ml 1 SI Interferon alpha 2b ± ± 1.04 RBV 0.11 ± ± Oseltamivir phosphate >40 ± 0.00 >2.95 ± 0.00 Amantadine >20 ± 0.00 >1.84 ± A549 RNA CPE,, qrt-pcr A 1 4 4, A/FM/1/47 (/H1N1) : α2b IC 50 < 48 U ml 1, SI >6 250; 200 μg ml %; 10 μg ml %; 10 μg ml % Table 4 The inhibition of recombinant human interferon alpha 2b on influenza virus A RNA (IC 50, U ml 1 ) (qrt-pcr) Virus IC 50 /U ml 1 Interferon alpha 2b JXDH ± > ± FM1 <48 ± 0.00 >6 250 ± 0.00 LNZX <48 ± 0.00 >6 250 ± 0.00 FJTA ± ± A/ /196/2009 (H3N2) : α2b IC U ml 1, SI > ; 200 μg ml %; 10 μg ml 1 SI Figure 1 The inhibitory activity of drugs on influenza virus A (FM1) RNA (qrt-pcr). ** P < 0.01 vs FM1 Figure 2 The inhibition of drugs on influenza virus A (FJTA) RNA (qrt-pcr). ** P < 0.01 vs FJTA

6 1552 Acta Pharmaceutica Sinica 2014, 49 (11): Figure 3 The inhibition of drugs on influenza virus A (LNZX) RNA (qrt-pcr). ** P < 0.01 vs LNZX Figure 4 The inhibition of drugs on influenza virus A (JXDH) RNA (qrt-pcr). * P < 0.05, ** P < 0.01 vs JXDH 30.15%; 10 μg ml % A/ /1109/2010 (H1N1) : α2b IC 50 < 48 U ml 1, SI > 6 250; 200 μg ml %; 10 μg ml %; 10 μg ml % A/ /312/2006 (H3N2) : α2b IC U ml 1, SI > ; 200 μg ml %; 10 μg ml %; 10 μg ml %, α2b A RNA,,,, , RNA DNA,,,,,, [10, 11],, (IFN),,, [12] IFN,, [13], 2', 5'- (OAS) (PKR) IFITM3 Mx [14],,

7 : α2b 1553 [1, 7],,,,,,, Alferon N, H7N9 [15] α2b,, α2b α α2b CPE MTT qrt-pcr, α2b α2b, α2b,,, α2b α2b, α2b, α2b References [1] Gao LL, Yu SY, Chen Q, et al. A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits [J]. Vaccine, 2010, 28: [2] Paranhos-Baccala G, Komurian-Pradel F, Richard N, et al. Mixed respiratory virus infections [J]. J Clin Virol, 2008, 43: [3] Nguyen-Van-Tam JS, Sellwood C. Intervention strategies for emerging respiratory virus infections: policy and public health considerations [J]. Curr Opin Virol, 2013, 3: [4] Shen Z, Chen Z, Li X, et al. Host immunological response and factors associated with clinical outcome in patients with the novel influenza A H7N9 infection [J]. Clin Microbiol Infect, 2013, 20: O493 O500. [5] Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges [J]. Annu Rev Med, 2013, 64: [6] Chen HS, Zhang XQ. Antivirus Drug: Methods and Applications: Vol 20 ( : 20 ) [M]. Beijing: Chemical Industry Press, 2006: 328. [7] Yu DX, Chen Q, Zhang LL, et al. A field trial of recombinant human interferon α-2b for nasal spray to prevent SARS and other respiratory viral infections [J]. Chin J Exp Clin Viro ( ), 2005, 19: [8] Fensterl V, Sen GC. Interferons and viral infections [J]. Biofactors, 2009, 35: [9] Chevaliez S, Pawlotsky JM. Interferons and their use in persistent viral infections [J]. Handb Exp Pharmacol, 2009: [10] Zu M, Zhou D, Gao L, et al. Evaluation of Chinese traditional patent medicines against influenza virus in vitro [J]. Acta Pharm Sin ( ), 2010, 45: [11] Zhang Q, Zhao QJ, Xiong RS, et al. Research progress of anti-influenza virus agents [J]. Acta Pharm Sin ( ), 2010, 45: [12] de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions [J]. J Biol Chem, 2007, 282: [13] van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses [J]. Viruses, 2012, 4: [14] Wang X, Hinson ER, Cresswell P. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts [J]. Cell Host Microbe, 2007, 2: [15] Liu Q, Ma J, Strayer DR, et al. Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment [J]. Expert Rev Anti Infect Ther, 2014, 12: